Riskpilot← Back to searchSign inGet full accessChiesi Pharma AB
ABActiveOrg 5568275746Klara Norra Kyrkogata 34 5trWholesale of pharmaceutical and medical goods · NACE 4646Est. 2010109 employees
Revenue 2024
SEK 870,5M
+18% vs 2023
EBITDA margin
6.0%
+32% vs 2023
Equity ratio
45.0%
Financial strength
Net profit 2024
SEK 33,4M
+30% vs 2023
| Revenue | SEK 870,5M | +18% |
| EBITDA | SEK 52M | +32% |
| Net profit | SEK 33,4M | +30% |
| Total assets | SEK 292,9M | -14% |
| Equity | SEK 131,8M | +34% |
| Employees | 109 | — |
Legal name
Chiesi Pharma AB
Org number
5568275746
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24 november 2010
Share capital
SEK 50 000
Employees
109 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva forskning och utveckling, marknadsföring och försäljning av läkemedel i Norden samt därmed förenlig verksamhet. Bolaget avser att: (i) verka på ett ansvarsfullt, hållbart, öppet och transparent sätt gentemot människor, samhällen och miljö i syfte att främja hälsa, inkludering och rättvisa samt (ii) kontinuerligt bli alltmer hållbara i processer och metoder, för att mildra de negativa effekterna och maximera fördelarna för människor, biosfären och planeten, i riktning mot en ekonomi med netto-noll utsläpp av växthusgaser och i linje med nationella och internationella mål om klimatneutralitet och ekologisk omställning.
Address
Klara Norra Kyrkogata 34 5tr
Email
o.fromm@chiesi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 276 939 | 506 939 | 638 756 | 738 731 | 870 456 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 17 666 | 38 023 | 42 787 | 39 224 | 51 967 |
| Depreciation & amort. | −3 799 | −5 322 | −6 286 | −6 913 | −7 917 |
| EBIT | 13 867 | 32 701 | 36 501 | 32 311 | 44 050 |
| Net financials | −981 | −3 184 | −11 333 | 2 002 | 1 476 |
| Profit before tax | 12 886 | 30 989 | 30 827 | 34 312 | 45 578 |
| Tax | −3 833 | −6 611 | −6 188 | −8 558 | −12 192 |
| Net profit | 9 053 | 24 378 | 24 639 | 25 754 | 33 386 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 214 580 | 302 150 | 305 420 | 340 876 | 292 881 |
| Equity | 23 682 | 48 060 | 72 703 | 98 457 | 131 843 |
| Long-term debt | 50 172 | 51 252 | 33 365 | 0 | 0 |
| Short-term debt | 140 727 | 202 838 | 199 352 | 242 419 | 161 038 |
| Total debt | 190 899 | 254 090 | 232 717 | 242 419 | 161 038 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20202024
Equity ratio
45.0%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
25.3%
This company
18.4%
Market median
+38% vs market
20202024
Net profit margin
3.8%
This company
8.1%
Market median
-53% vs market
20202024
Asset turnover
2.97×
This company
1.12×
Market median
+165% vs market
20202024
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PE Chief Auditor | Chief Auditor | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2024 | |
| Board of Directors | 2022 | |
| Board of Directors | 2021 | |
| Chairman | 2022 | |
| Former (4) | ||
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2022 – 2025 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHIESI FARMACEUTICI SPA
Chiesi Pharma AB (this company)Board members of Chiesi Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Esbjörn Svensson | Chief Auditor | 0 companies |
| Marco Vecchia | Board of Directors | 0 companies |
| Giulia Cuccagna | Board of Directors | 0 companies |
| Michael Russell Gordon | Board of Directors | 0 companies |
| Filiz Balcay | Board of Directors | 0 companies |
| Anna Helena Bergström | Board of Directors | 0 companies |
| Véronique Magro | Board of Directors | 0 companies |
| Jose Fernando Albertini de Almedia | Chairman | 0 companies |
| Marco Rombi | Board of Directors | 0 companies |
| Olav Henrik Fromm | Chairman | 0 companies |